Tc-99m-N-MPO: Novel cationic Tc-99m radiotracer for myocardial perfusion imaging

Journal of Nuclear Cardiology

Volumn 15, Issue 4, 2008, Pages 535-546

  Kim, Young Seung ^a   Wang, Jianjun ^a   Broisat, Alexis ^b   Glover, David K ^b   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cationic technetium 99m radiotracers; myocardial perfusion imaging

Indexed keywords

DRUG METABOLITE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOISOTOPE; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; ECHO PLANAR IMAGING; FEMALE; HEART PERFUSION; LIVER METABOLISM; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOCARDIOGRAPHY; RAT;

ANIMALS; CATIONS; FEMALE; GUINEA PIGS; HEART VENTRICLES; HUMANS; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 47949104483     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2008.02.022     Document Type: Article

References (45)

1. Nunn A.D. Radiopharmaceuticals for imaging myocardial perfusion. Semin Nucl Med 20 (1990) 111-118
2. Saha G.B., Go R.T., and Macintyre W.J. Radiopharmaceuticals for cardiovascular imaging. Nucl Med Biol 19 (1992) 1-20
3. Opie L.H., and Hesse B. Radionuclide tracers in the evaluation of resting myocardial ischaemia and viability. Eur J Nucl Med 24 (1997) 1183-1193
4. Berman D.S., Germano G., and Shaw L.J. The role of nuclear cardiology in clinical decision making. Semin Nucl Med 29 (1999) 280-297
5. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med 29 (1999) 221-236
6. Acampa W., Di Benedetto C., and Cuocolo A. An overview of radiotracers in nuclear cardiology. J Nucl Cardiol 7 (2000) 701-707
7. Dilsizian V. The role of myocardial perfusion imaging in vascular endothelial dysfunction. J Nucl Cardiol 7 (2000) 180-184
8. Beller G.A., and Zaret B.L. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 101 (2000) 1465-1478
9. Banerjee S., Pillai M.R.A., and Ramamoorthy N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med 31 (2001) 260-277
10. Parker J.A. Cardiac nuclear medicine in monitoring patients with coronary heart disease. Semin Nucl Med 31 (2001) 223-237
11. Kapur A., Latus K.A., Davies G., Dhawan R.T., Eastick S., Jarritt P.H., et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: The ROBUST study. Eur J Nucl Med 29 (2002) 1608-1616
12. Kailasnath P., and Sinusas A.J. Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: Technical, physiological, and clinic issues. J Nucl Cardiol 8 (2001) 482-498
13. Llaurado J.G. The quest for the perfect myocardial perfusion indicator . . . still a long way to go. J Nucl Med 42 (2001) 282-284
14. Jones A.G., Abrams M.J., Davison A., Brodack J.W., Toothaker A.K., Adelstein S.J., et al. Biological studies of a new class of technetium complexes: The hexakis(alkylisonitrile)technetium(I) cations. Int J Nucl Biol 11 (1984) 225-234
15. Wackers F.J.T., Berman D.S., Maddahi J., Watson D.D., Beller G.A., Strauss H.W., et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to Tl-201 for myocardial perfusion imaging. J Nucl Med 30 (1989) 301-311
16. Iskandrian A.S., Heo J.Y., Kong B., Lyons E., and Marsch S. Use of technitium-99m isonitrile (RP-30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease and comparison with coronary arteriography and exercise thallium-201 SPECT imaging. Am J Cardiol 64 (1989) 270-275
17. 2en = N,N′-ethylenebis[acetylacetone iminato]). Nucl Med Biol 26 (1999) 755-770
18. + complexes containing ether analogs of DMPE. Nucl Med Biol 26 (1999) 563-571
19. - = thiolate). J Med Chem 39 (1996) 1253-1261
20. 99mTc heterocomplexes as heart imaging agents with improved biological properties. Nucl Med Commun 23 (2002) 689-693
21. 99mTc-nitride heterocomplexes showing high heart uptake and improved imaging properties. J Nucl Med 44 (2003) 806-814
22. 99mTc-tetrofosmin in rats. J Nucl Med 45 (2004) 2095-2101
23. Hatada K., Ruiz M., Riou L.M., Lima R.L., Goode A.R., Watson D.D., et al. Organ distribution and myocardial uptake, washout, and redistribution kinetics of Tc-99m N-DBODC5 when injected during vasodilator stress in canine models of coronary stenoses. J Nucl Cardiol 13 (2006) 779-790
24. 99mTc complexes useful as radiopharmaceuticals for heart imaging. Dalton Trans (2007) 1183-1193
25. 99mTc-nitrido complexes radiopharmaceuticals for heart imaging: Improving liver clearance with crown ether groups. Nucl Med Biol 33 (2006) 419-432
26. 99mTc radiotracers. Inorg Chim Acta 359 (2006) 2479-2488
27. 99mTc(I)-tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging. Nucl Med Biol 33 (2006) 1045-1053
28. 99mTc-nitrido complexes. Bioconjug Chem 18 (2007) 929-936
29. 99mTc-labeling of small biomolecules. Bioconjug Chem 17 (2006) 473-484
30. Piwnica-Worms D., Kronauge J.F., and Chiu M.L. Uptake and retention of hexakis(2-methoxyisobutylisonitrile) technetium(I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 82 (1990) 1826-1838
31. Carvalho P.A., Chiu M.L., Kronauge J.F., Kawamura M., Jones A.G., Holman B.L., et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33 (1992) 1516-1521
32. Crane P., Laliberte R., Heminway S., Thoolen M., and Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 20 (1993) 20-25
33. Duchen M.R. Mitochondria in health and disease: Perspectives on a new mitochondrial biology. Mol Aspects Med 25 (2004) 365-451
34. 99mTc complexes. Nucl Med Biol 16 (1989) 191-232
35. Gatmaitan Z.C., and Arias I.M. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24 (1993) 77-97
36. Lee C.H., Bradley G., Zhang J.T., and Ling V. Differential expression of P-glycoprotein genes in primary rat hepatocytes culture. J Cell Physiol 157 (1993) 392-402
37. Mayer R., Kartenbeck J., Buchler M., Jedlitschky G., Leier I., and Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport deficient mutant hepatocytes. J Cell Biol 131 (1995) 137-150
38. 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol Imaging 1 (2002) 24-35
39. 99mTc-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nucl Med Commun 20 (1999) 115-122
40. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging 31 (2004) S88-S96
41. Sharma V., and Piwnica-Worms D. Metal complexes for therapy and diagnosis of drug resistance. Chem Rev 99 (1999) 2545-2560
42. Sharma V. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjug Chem 15 (2004) 1464-1474
43. Vaidyanathan G., and Zalutsky M.R. Imaging drug resistance with radiolabeled molecules. Curr Pharm Des 10 (2004) 2965-2979
44. Luker G.D., Francasso P.M., Dobkin J., and Piwbica-Worms D. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m sestamibi in vivo. J Nucl Med 38 (1997) 369-372
45. 99mTc-Sestamibi accumulation in normal liver and drug resistant-tumors after administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 9 (2003) 650-656